Home / Tag Archives: astrazeneca (page 4)

Tag Archives: astrazeneca

October, 2017

August, 2017

July, 2017

  • 31 July

    FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer

    AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. Sean Bohen, …

  • 28 July

    AstraZeneca’s Imfinzi Fails to Meet Primary Endpoint in Late-Stage Lung Cancer Trial

    AstraZeneca and MedImmune, its global biologics research and development arm, today announced progression-free survival (PFS) results for the Phase III MYSTIC trial, a randomized, open-label, multi-center, global trial of Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab versus platinum-based standard-of-care (SoC) chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung …

  • 28 July

    Merck and AstraZeneca Enter Strategic Oncology Collaboration

    ENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types. LYNPARZA is an innovative, first-in-class oral poly ADP …

  • 27 July

    AstraZeneca’s Tagrisso Significantly Improves Progression-Free Survival in Late-Stage NSCLC Study

    AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment (erlotinib or gefitinib) in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). Sean Bohen, Executive Vice …